New York State Common Retirement Fund bought a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 85,567 shares of the medical instruments supplier’s stock, valued at approximately $321,000.

Other large investors have also recently modified their holdings of the company. Ameriprise Financial Inc. purchased a new position in Harvard Bioscience in the 2nd quarter worth approximately $752,000. Foundry Partners LLC boosted its holdings in Harvard Bioscience by 10.2% in the 3rd quarter. Foundry Partners LLC now owns 754,820 shares of the medical instruments supplier’s stock worth $2,831,000 after acquiring an additional 70,045 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Harvard Bioscience by 4.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,710,722 shares of the medical instruments supplier’s stock worth $4,362,000 after acquiring an additional 79,374 shares during the period. First Light Asset Management LLC boosted its holdings in Harvard Bioscience by 11.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,572,196 shares of the medical instruments supplier’s stock worth $9,109,000 after acquiring an additional 367,711 shares during the period. Finally, Essex Investment Management Co. LLC boosted its holdings in Harvard Bioscience by 25.9% in the 3rd quarter. Essex Investment Management Co. LLC now owns 540,819 shares of the medical instruments supplier’s stock worth $2,028,000 after acquiring an additional 111,359 shares during the period. Institutional investors and hedge funds own 61.68% of the company’s stock.

Harvard Bioscience, Inc. (HBIO) opened at $3.85 on Monday. The firm has a market capitalization of $134.29, a P/E ratio of -42.78 and a beta of 1.10. Harvard Bioscience, Inc. has a fifty-two week low of $2.25 and a fifty-two week high of $3.90. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.40 and a quick ratio of 1.87.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.03 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.03. The firm had revenue of $25.05 million during the quarter, compared to analysts’ expectations of $24.60 million. Harvard Bioscience had a positive return on equity of 1.11% and a negative net margin of 3.16%. equities analysts forecast that Harvard Bioscience, Inc. will post 0.05 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “New York State Common Retirement Fund Invests $321,000 in Harvard Bioscience, Inc. (HBIO)” was published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/new-york-state-common-retirement-fund-invests-321000-in-harvard-bioscience-inc-hbio/1798314.html.

Harvard Bioscience Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.